AccuMetab™ Human CYP17A1 Enzyme, Catalytically Active

CAT#: ITS-0426-YL14
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Human CYP17A1 for accurate Phase I drug metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
CYP17A1 is a dual-function steroidogenic enzyme essential for the biosynthesis of androgens and estrogens from cholesterol precursors. It is extensively utilized as a primary drug target for prostate cancer therapeutics and as a counter-screen for unintended endocrine disruption in early toxicology testing.
Key Features
Proprietary E. coli expression; High and low reductase ratio options; Dual-function steroidogenic enzyme model; Gold-standard target for prostate cancer therapeutics
Applications
Drug Metabolism Studies, Reaction Phenotyping, DDI Assessment, Metabolite ID
Research Areas
ADME; Oncology; Endocrinology
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry